Chappidi Meera R, Kates Max, Johnson Michael H, Hahn Noah M, Bivalacqua Trinity J, Pierorazio Phillip M
The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD.
The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD.
Urol Oncol. 2016 Dec;34(12):531.e15-531.e24. doi: 10.1016/j.urolonc.2016.06.013. Epub 2016 Jul 27.
The purpose of the study was to characterize the contemporary trends in lymphadenectomy for the treatment of upper tract urothelial carcinoma in a population-based cohort and to determine if number of lymph nodes removed and tumor location are predictors of cancer-specific survival in patients undergoing nephroureterectomy.
Individuals with upper tract urothelial carcinoma undergoing nephroureterectomy in the Surveillance, Epidemiology, and End Results program from 2004 to 2012 were identified. Linear regression was used to assess trends in lymphadenectomy. Patients were stratified based on nodal status, quartiles of nodes removed, and tumor location. Kaplan-Meier analysis, log-rank tests, and Cox proportional hazards models were used to compare cancer-specific survival and overall survival among groups.
In the cohort, 25% (721/2,862) of all patients and 27% (566/2,079) of grade 3/4 patients underwent lymphadenectomy. The percentage of patients undergoing lymphadenectomy increased from 20% (60/295) in 2004 to 33% (106/320) in 2012 (P = 0.02). Patients with the highest quartile of lymph nodes removed had improved the 5-year cancer-specific survival of 78% (95% CI: 69%-85%) compared to the second quartile (60%; 95% CI: 51%-67%; P = 0.003) and the third quartile (60%; 95% CI: 51%-68%; P = 0.002) of nodes removed. This trend held for node-negative and node-positive patients. In multivariable modeling, a lower number of lymph nodes dissected (hazard ratio = 0.94, 95% CI: 0.91-0.98) and ureteral tumors (hazard ratio = 1.29, 95% CI: 1.07-1.56) were predictors of worse cancer-specific survival.
In patients with upper tract urothelial carcinoma undergoing nephroureterectomy, rates of lymphadenectomy have increased from 2004 to 2012 in the United States. In this contemporary cohort, an increase in the number of nodes removed and renal pelvis tumors are associated with improved cancer-specific survival, which highlights the importance of intentional lymph node dissection with adequate lymph node yield in these patients.
本研究的目的是描述基于人群队列中用于治疗上尿路尿路上皮癌的淋巴结清扫术的当代趋势,并确定切除的淋巴结数量和肿瘤位置是否为接受肾输尿管切除术患者癌症特异性生存的预测因素。
确定2004年至2012年在监测、流行病学和最终结果计划中接受肾输尿管切除术的上尿路尿路上皮癌患者。使用线性回归评估淋巴结清扫术的趋势。根据淋巴结状态、切除淋巴结的四分位数和肿瘤位置对患者进行分层。使用Kaplan-Meier分析、对数秩检验和Cox比例风险模型比较各组的癌症特异性生存和总生存。
在该队列中,所有患者的25%(721/2862)和3/4级患者的27%(566/2079)接受了淋巴结清扫术。接受淋巴结清扫术的患者百分比从2004年的20%(60/295)增加到2012年的33%(106/320)(P = 0.02)。切除淋巴结四分位数最高的患者5年癌症特异性生存率为78%(95%CI:69%-85%),高于切除淋巴结第二四分位数(60%;95%CI:51%-67%;P = 0.003)和第三四分位数(60%;95%CI:51%-68%;P = 0.002)的患者。这种趋势在淋巴结阴性和阳性患者中均成立。在多变量模型中,切除的淋巴结数量较少(风险比 = 0.94,95%CI:0.91-0.98)和输尿管肿瘤(风险比 = 1.29,95%CI:1.07-1.56)是癌症特异性生存较差的预测因素。
在美国,2004年至2012年期间,接受肾输尿管切除术的上尿路尿路上皮癌患者的淋巴结清扫率有所增加。在这个当代队列中,切除的淋巴结数量增加和肾盂肿瘤与改善的癌症特异性生存相关,这突出了在这些患者中进行有意的淋巴结清扫并获得足够淋巴结数量的重要性。